Researchers found that sialidase inhibitors—a class of flu drugs including oseltamivir (Tamiflu)—protected against degradation of protective sugar molecules tied to cognitive decline and premature aging in people living with HIV.
Researchers found that sialidase inhibitors—a class of flu drugs including oseltamivir (Tamiflu)—protected against degradation of protective sugar molecules tied to cognitive decline and premature aging in people living with HIV.
Read More
Researchers found that five core values—safety, knowledge, trust, humanity, and autonomy—shape how minority parents approach pediatric vaccination.
Read More
Combining formoterol and methacholine significantly improves mucociliary clearance in animal models of cystic fibrosis, compared to using either drug alone.
Read More
Researchers at Adelaide University developed a lipid-polymer vehicle that improves drug bioavailability and reduces systemic toxicity in preclinical models of lung cancer.
Read More
For every 100 children vaccinated against influenza, between nine and 14 cases are prevented, according to Harvard Medical School data.
Read More
Updated clinical data demonstrates that Papzimeos for adults with Recurrent Respiratory Papillomatosis (RRP) can maintain complete responses for more than four years.
Read More
Researchers developed an avian flu vaccine platform that generates immunity in the respiratory tract and bloodstream to combat H5N1.
Read More
A study of over 1.1 million American adults with asthma found that Black, Hispanic, and Asian patients use ICS, LABA and LAMA inhalers less frequently than white patients.
Read More
Phase 3 clinical trial data shows improvements in walking distance and duration for patients with autoimmune pulmonary alveolar proteinosis treated with inhaled molgramostim.
Read More
Phase 3 trial results show significant reductions in clinical worsening and acute exacerbations for patients with idiopathic pulmonary fibrosis (IPF).
Read More
Phase 1 data for the investigational inhaled nitric oxide therapy Alx1 demonstrated the treatment was well tolerated with no serious side effects in healthy volunteers.
Read More
AERO-007 demonstrated significant lung function improvements over 24 hours in patients with moderate-to-severe COPD.
Read More
Phase 2 data for efdoralprin alfa demonstrate the recombinant protein maintains normal protein levels with less frequent dosing than current standards of care for patients with alpha-1 antitrypsin deficiency (AATD)-related emphysema.
Read More
A new study shows tezepelumab (Tezspire) reduced asthma exacerbations by 70% across all patient subgroups, including smokers and those with comorbid conditions.
Read More
A phase 3 trial found that AD109 (aroxybutynin and atomoxetine) reduced breathing interruptions and improved oxygen levels in patients with obstructive sleep apnea.
Read More
Benralizumab (Fasenra) is now indicated to reduce the risk of flare ups for adult and pediatric patients with hypereosinophilic syndrome.
Read More
Enanta Pharmaceuticals will present data on its RSV therapy zelicapavir and on EPS-3903, an oral STAT6 inhibitor, at ATS 2026.
Read More
Data from clinical trials investigating treatments for pulmonary hypertension and pulmonary fibrosis will be highlighted at ATS 2026.
Read More
Phase 1 results for the inhaled drug candidate ALX1 focus on safety and pharmacokinetics for the treatment of serious lung diseases.
Read More
The once-weekly INNA-051 treatment from ENA Respiratory aims to prime the immune system to protect high-risk patients from influenza, RSV, and other respiratory viruses.
Read More
The COPD-OMA trial will examine if the asthma drug omalizumab (Xolair) benefits COPD patients with sensitivities to indoor allergens.
Read More
The MIRANDA study found tozorakimab significantly lowered the rate of moderate-to-severe respiratory worsening in patients regardless of smoking history or specific white blood cell counts.
Read More
The single-inhaler therapy Breztri Aerosphere is now indicated for maintenance treatment in adults and pediatric patients who remain symptomatic on dual therapies.
Read More
An NFID initiative provided evidence-based guidance on influenza, COVID-19, and RSV during the 2025-2026 season.
Read More
